CPSE:ALK BPharmaceuticals
A Look At ALK‑Abelló (CPSE:ALK B) Valuation After New EURneffy Preference Data At AAAAI 2026
ALK-Abelló (CPSE:ALK B) shares are in focus after the company reported new EURneffy user data at the AAAAI 2026 meeting, with 88% of trial participants preferring the needle free nasal adrenaline treatment to auto injectors.
See our latest analysis for ALK-Abelló.
The AAAAI data arrive after a softer patch for the shares, with a 1 day share price return of a 2.01% decline and a 7 day share price return of a 4.04% decline, even though the 1 year total shareholder return is 55.41% and the 3...